Jing Ai, MD

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).